Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated wit…

First global approval of a once-daily, orally administered, Complement Factor B inhibitorApproval based on robust efficacy ...

Nuvectis’ NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor

It is the first once-daily oral Complement Factor B inhibitor ever approved, anywhere in the world. A second Chinese application, on the same molecule, covering PNH patients who have failed prior C5 ...
BioWorld

Complement factor B inhibitors reported in Hansoh patent

A Hansoh Bio LLC, Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. patent details piperidinyl indole derivatives acting as complement factor B (CFB) inhibitors.
Renal & Urology News

Complement Activation Implicated in Acute Kidney Injury

Findings suggest that the complement system plays a role in the onset of acute kidney injury in critically ill patients. Urinary Ba, a fragment of complement factor B, may be a biomarker and mediator ...
BioWorld

Novartis identifies new complement factor B inhibitors

Complement factor B (CFB) inhibitors are described in a Novartis AG patent and reported to be useful for the treatment of age-related macular degeneration, diabetic retinopathy and eye disorders, ...
Business Insider

Nuvectis' NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor

Nuvectis Pharma (NASDAQ: NVCT) announced this morning that ciprocopan (NXP100) has been approved by China's National Medical Products Administration (NMPA) for the treatment of adult patients with ...